[{"id":"9ff75a13-e0fb-4659-a12b-a20b35ef7bb8","acronym":"FLAMINGO-01","url":"https://clinicaltrials.gov/study/NCT05232916","created_at":"2022-02-10T14:52:54.352Z","updated_at":"2025-02-25T13:40:51.671Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects","source_id_and_acronym":"NCT05232916 - FLAMINGO-01","lead_sponsor":"Greenwich LifeSciences, Inc.","biomarkers":" HER-2 • HLA-A","pipe":" | ","alterations":" HLA-A*02 positive","tags":["HER-2 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • GLSI-100 • GP2"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"980e1068-fd01-44b1-b3ab-8466fd9acc2c","acronym":"BAMC-C.2007.098","url":"https://clinicaltrials.gov/study/NCT00524277","created_at":"2021-01-18T01:53:39.730Z","updated_at":"2024-07-02T16:36:47.236Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00524277 - BAMC-C.2007.098","lead_sponsor":"San Antonio Military Medical Center","biomarkers":" HER-2 • ER • PGR • CSF2","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative","tags":["HER-2 • ER • PGR • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AE 37 • GLSI-100 • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 456","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 12/31/2014","primary_completion_date":" 12/31/2014","study_txt":" Completion: 03/31/2017","study_completion_date":" 03/31/2017","last_update_posted":"2020-03-30"},{"id":"ef9486dd-27f7-4bf8-b991-6f22d2a0d1ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03014076","created_at":"2021-01-18T14:49:55.762Z","updated_at":"2024-07-02T16:37:26.702Z","phase":"Phase 1","brief_title":"Immunotherapy Vaccine and Herceptin in Breast Cancer","source_id_and_acronym":"NCT03014076","lead_sponsor":"Cancer Insight, LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • GLSI-100"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-01-09"}]